Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;67(3):264-9.
doi: 10.5173/ceju.2014.03.art11. Epub 2014 Aug 18.

A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals

Cristian Persu  1 , Emmanuel Braschi  2 , John Lavelle  3
Affiliations
Review

A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals

Cristian Persu et al. Cent European J Urol. 2014.

Abstract

Introduction: The neurogenic urinary bladder is defined as a dysfunctional bladder associated with a known neurological injury. We review the data from good quality clinical trials looking at drug therapy for the neurogenic bladder.

Materials and methods: IN ORDER TO IDENTIFY AS MANY PROSPECTIVE TRIALS AS POSSIBLE, WE PERFORMED INTERNET SEARCHES, USING THE SAME SEARCH STRING: Urinary Bladder, neurogenic (MESH). In each case, the search was limited to clinical trial, prospective trial, subjects were human and the language was English. There was no year limit for our search. The next step was duplicate removal, which led to a final number of 580 papers. We defined clear inclusion criteria for the papers.

Results: A total of 82 full text papers were reviewed and analyzed according to the previously mentioned algorithm. The oldest two prospective clinical trials date back to 1976, with an obvious increase in number of trials each year, reaching more than five trials per year after 2001, which demonstrates increased interest toward the subject. The total number of patients included in the trials is 3904, 888 of which are children. The male: female ratio is close to 1, although there were 9 studies where no information regarding the sex of the patients was available.

Conclusions: Our analysis stresses the acute need for good quality trials looking at the drugs used for the management of the patients with neurogenic bladders, with adequate statistical power to support the data they present.

Keywords: antimuscarinics; botulinum toxin; clinical trial; drug therapy; neurogenic bladder.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of trials for each ten year period.
Figure 2
Figure 2
Main conditions behind the neurogenic bladder.
Figure 3
Figure 3
Pediatric conditions behind the neurogenic bladder.
Figure 4
Figure 4
Number of trials for each ten year period sorted by source of funding.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Klausner AP, Steers WD. The neurogenic bladder: an update with management strategies for primary care physicians. Med Clin North Am. 2011;95:111–120. - PubMed
    1. Wyndaele JJ, Kovindha A, Madersbacher H, Radziszewski P, Ruffion A, Schurch B, et al. Committe 10 on Neurogenic Bladder and Bowel of the International Consultation on Incontinence 2008–2009. Neurologic urinary incontinence. Neurourol Urodyn. 2010;29:159–164. - PubMed
    1. Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V, Artibani W. A systematic review and meta–analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–763. - PubMed
    1. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health–care providers. J Spinal Cord Med. 2006;29:527–573. - PMC - PubMed
    1. Moher D, Hopewell S, Schulz KF, Altman DG. Resources for authors of reports of randomized trials: harnessing the wisdom of authors, editors, and readers. Trials. 2011;12:98. - PMC - PubMed

LinkOut - more resources